Medication info

Dobutamine Hydrochloride Injection

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Dobutamine Hydrochloride›56.06mg / 1mL
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow transparent liquid or a colorless transparent ampule injection.
Packaging
1 ampule (5mL) X 50 ampules
Approval status
Active

MFDS item code 199702368 · Notified 1997.02.26 · Insurance code 657802541

Summary

Main use
Short-term treatment of heart failure due to heart disease or cardiac surgery
Who receives it
Adults
Adult administration
Adults: Administer dobutamine intravenously at 2.5-10㎍/kg of body weight/min (see table). In rare cases, an infusion rate of 40㎍/kg of body weight/min may be required to achieve a satisfactory effect. In patients with atrial fibrillation and a rapid cardiac output, use a digitalis preparation before treatment with this medicine. The infusion rate and duration of treatment should be adjusted according to the patient's response, as determined by heart rate, presence of ectopic activity, blood pressure, urine output, central venous pressure or pulmonary wedge pressure when measurable, and cardiac output. Administration to humans at concentrations up to 5,000㎍/㎖ (250mg/50㎖) has been reported. The final administered dose is determined by the patient's fluid requirements. Adjust the dose as appropriate according to age and symptoms. 2. Diluent For intravenous injection, dilute in at least 50㎖ of one of the following solutions: 5% and 10% glucose injection, 5% glucose in 0.45% saline injection, 5% glucose in 0.9% saline injection, Isolyte RM injection containing 5% glucose, lactated Ringer's solution, 5% glucose in lactated Ringer's solution, Normosol RM in D5-W, 20% OsmitrolR injection dissolved in water for injection, 0.9% saline injection, sodium lactate injection, etc. Infusion rates for concentrations of 250, 500, and 1000㎍/㎖ Drug infusion rate (㎍/kg/min) — Diluent infusion rate 250㎍/㎖ (㎖/kg/min), 500㎍/㎖ (㎖/kg/min), 1000㎍/㎖ (㎖/kg/min) 2.5 — 0.01 — 0.005 — 0.0025 5 — 0.02 — 0.01 — 0.005 7.5 — 0.03 — 0.015 — 0.0075 10 — 0.04 — 0.02 — 0.01 12.5 — 0.05 — 0.025 — 0.0125 15 — 0.06 — 0.03 — 0.015

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Short-term treatment of heart failure due to heart disease or cardiac surgery

View approved original text

This medication is used for the short-term treatment of heart failure patients with decreased contractility after cardiac disease or surgery. It primarily helps improve heart function by increasing cardiac output. This enhances blood circulation and overall heart function, assisting in stabilizing the patient's condition during the treatment period. These effects contribute to alleviating patient's symptoms and improving quality of life. Therefore, this drug is used to enhance cardiac output.

How it is given

Adult administration

Adults: Administer dobutamine intravenously at 2.5-10㎍/kg of body weight/min (see table). In rare cases, an infusion rate of 40㎍/kg of body weight/min may be required to achieve a satisfactory effect. In patients with atrial fibrillation and a rapid cardiac output, use a digitalis preparation before treatment with this medicine. The infusion rate and duration of treatment should be adjusted according to the patient's response, as determined by heart rate, presence of ectopic activity, blood pressure, urine output, central venous pressure or pulmonary wedge pressure when measurable, and cardiac output. Administration to humans at concentrations up to 5,000㎍/㎖ (250mg/50㎖) has been reported. The final administered dose is determined by the patient's fluid requirements. Adjust the dose as appropriate according to age and symptoms. 2. Diluent For intravenous injection, dilute in at least 50㎖ of one of the following solutions: 5% and 10% glucose injection, 5% glucose in 0.45% saline injection, 5% glucose in 0.9% saline injection, Isolyte RM injection containing 5% glucose, lactated Ringer's solution, 5% glucose in lactated Ringer's solution, Normosol RM in D5-W, 20% OsmitrolR injection dissolved in water for injection, 0.9% saline injection, sodium lactate injection, etc. Infusion rates for concentrations of 250, 500, and 1000㎍/㎖ Drug infusion rate (㎍/kg/min) — Diluent infusion rate 250㎍/㎖ (㎖/kg/min), 500㎍/㎖ (㎖/kg/min), 1000㎍/㎖ (㎖/kg/min) 2.5 — 0.01 — 0.005 — 0.0025 5 — 0.02 — 0.01 — 0.005 7.5 — 0.03 — 0.015 — 0.0075 10 — 0.04 — 0.02 — 0.01 12.5 — 0.05 — 0.025 — 0.0125 15 — 0.06 — 0.03 — 0.015

Precautions

This drug is an ampule injection, and care must be taken when breaking the glass container to avoid glass fragments from contaminating the solution, especially when administering to children or the elderly. This medication should not be administered to certain patients, including those with idiopathic hypertrophic subaortic stenosis, those with hypersensitivity to this drug or who have previously shown allergic reactions, patients with constrictive pericarditis or cardiac tamponade. Caution should be exercised when administering to patients with increased heart rate or blood pressure, severe coronary artery disease, atrial fibrillation, patients with ventricular dyskinesia, and severe hypotension due to cardiogenic shock. Due to the sodium bisulfite component in this drug, allergic reactions or asthma attacks may occur in some patients, so special caution is necessary for asthma sufferers. During use, rare hypersensitivity reactions such as skin rash, fever, bronchospasm, and cardiac-related side effects may occur, including rapid heart rate, arrhythmias, blood pressure elevation, angina symptoms, shortness of breath, and hypotension. Gastrointestinal side effects may include abdominal pain or nausea, and redness or swelling may occur at the injection site. Headaches can also occur, albeit infrequently. Continuous monitoring of blood pressure, heart rate, electrocardiograms, and urine output should be conducted during administration, and adequate vascular constrictor treatment may be necessary for patients with acute circulatory failure. Treatment to increase blood volume should be performed prior to administering this drug to patients with hypovolemia. Additionally, patients taking beta-blockers may experience reduced effects of this drug. This drug's safety has not been established for patients with acute myocardial infarction, and if heart rate and blood pressure increase excessively, dosage reduction measures may be necessary. Prolonged administration beyond 72 hours may result in tolerance, necessitating dose adjustments. Cautions should be taken when used in conjunction with certain vasodilators, beta-blockers, or MAO inhibitors, as interactions may occur. Women who are pregnant or of childbearing potential should only use this drug when the therapeutic benefits outweigh the risks, as its safety has not been established. If breastfeeding, consider avoiding administration or discontinuing nursing. The safety and efficacy of this drug have not been sufficiently evaluated in pediatric patients. Elderly patients may have diminished physiological functions, so administration should start at lower doses with careful observation of their condition. This drug is administered only via intravenous infusion, and care should be taken to prevent drug leakage outside the blood vessel, as local inflammation or tissue damage may occur at the injection site. When diluting, it should not be mixed with certain alkaline solutions or specific medications, and should be used within 24 hours of preparation. In cases of overdose, changes in blood pressure or rapid heart rate may occur, necessitating cessation of administration or dose reduction until the patient's condition stabilizes. This drug has a short duration of action, often not requiring additional treatments.

Side effects

  • Rash
  • fever
  • eosinophilia
  • bronchospasm
  • tachycardia
  • ectopic beats
  • excessive blood pressure increase
  • angina
  • precordial warmth
  • chest discomfort
Show 9 more
  • palpitations
  • dyspnea
  • hypotension
  • stress-induced cardiomyopathy
  • abdominal pain
  • nausea
  • injection site erythema
  • injection site swelling
  • headache

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to protect it from air exposure, preferably kept away from direct sunlight and at room temperature. Room temperature typically refers to a range between 15 to 25 degrees Celsius, and extremes should be avoided.

Appearance and packaging

Appearance

A colorless to pale yellow transparent liquid or a colorless transparent ampule injection.

Package unit

1 ampule (5mL) X 50 ampules

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.